Stem Cell News

BioInformant's coverage of stem cell news includes iPS cells, mesenchymal stem cells, hematopoietic stem cells, neural stem cells and more.

As the first and only market research firm to specialize in stem cell news, BioInformant research has been cited by the Wall Street Journal, Xconomy, AABB, and Vogue Magazine.

Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry news.

Introducing WellSky — A New Approach to Health and Community Care

September 12, 2018 By Cade Hildreth, Founder & President Leave a Comment

Mediware Information Systems, Kinnser Software, and More Than 30 Leaders in Health IT Unite Under One New Brand, Providing Integrated Health and Community Care Solutions for Millions of Patients

Sept 11, 2018, Lenexa, Kan. — Mediware Information Systems, Inc., a portfolio company of TPG Capital, today announced its strategic transformation to WellSky, effectively merging more than 30 unique health care and human services brands. The name “WellSky” conveys both the company’s vision to elevate the quality of care through innovation and the breadth of its offerings across the continuum of care, including leading solutions and services for blood banks, home health agencies, hospices, rehab facilities, Area Agencies on Aging, and many others. [Read more…]

Novartis Receives Health Canada Approval of its CAR-T cell therapy, Kymriah™

September 6, 2018 By Cade Hildreth, Founder & President Leave a Comment

Kymriah, the first chimeric antigen receptor T cell (CAR-T) therapy approved in Canada, is manufactured individually for each patient
Novartis is working with qualified treatment centres to prepare for the delivery of this treatment for relapsed/refractory (r/r) pediatric and young adult B-cell ALL and adult r/r DLBCL indications

DORVAL, QC, Sept. 6, 2018 – Novartis is pleased to announce that following a Priority Review, Health Canada has approved Kymriah™ (tisagenlecleucel/ CTL019) the first chimeric antigen receptor T cell (CAR-T) therapy to receive regulatory approval in Canada.

Kymriah, a CD19-directed genetically modified autologous T-cell immunocellular therapy, is approved to treat two life-threatening cancers that have limited treatment options and historically poor outcomes, demonstrating the critical need for new therapies for these patients. [Read more…]

Celularity Acquires CariCord, Adds Biosourcing Assets, Establishes Relationship with ClinImmune Labs

September 4, 2018 By Cade Hildreth, Founder & President Leave a Comment

WARREN, N.J., Aug. 31, 2018 — Celularity, an allogeneic immuno-oncology and placental cell therapeutics company, today announced it entered into a definitive agreement to acquire CariCord, the family cord blood bank established by the University of Colorado and ClinImmune Labs. Through its exclusive ClinImmune Labs relationship, CariCord is the first, and so far the only family cord blood bank to operate inside a FDA Licensed Laboratory. ClinImmune Labs is an academic component of the School of Medicine at the University of Colorado at Denver and Health Sciences Center. Financial details of the transaction were not disclosed. [Read more…]

Cynata’s iPSC-derived Cell Therapeutic
(CYP-001) Meets Safety & Efficacy Endpoints

September 3, 2018 By Cade Hildreth, Founder & President 2 Comments

Cynata Therapeutics Ltd (ASX: CYP) is a clinical stage regenerative medicine company specializing in stem cell therapeutics that has a proprietary technology for manufacturing induced pluripotent stem cell (iPSC) derived mesenchymal stem cells (MSCs). Cynata is the only company in the world that can mass-produce therapeutic mesenchymal stem cells deriving from a single donor at a consistent quality and affordable cost. [Read more…]

StemTek and Biopredic International partner to deliver assay ready liver models

September 3, 2018 By Cade Hildreth, Founder & President Leave a Comment

Both companies plan to combine their respective technologies to deliver storable assay-ready 3D liver models for toxicology testing to reduce time and cost in new drug development.

August 21, 2018, Bilbao, Spain and Saint Grégoire, France — StemTek and Biopredic International are joining forces to design convenient, ready to use storable systems for toxicology screening on 3D liver cell models. 3D cell culture technology recapitulates the natural architecture of the tissue in a convenient laboratory format, producing more predictive data for in vivo tests. This technology allows a better understanding of the interaction of candidate compounds in areal physiological model, thus reducing drug failures. [Read more…]